BioSpace News Archive

Rockline Industries announced that the formula used in its hard surface disinfectant wipes has been approved by the U.S. Environmental Protection Agency to add claim language that the formula has been proven to kill SARS-CoV-2, the coronavirus that causes COVID-19, when used according to directions.

HJB, a biologics Contract Development and Manufacturing Organization (CDMO) committed to quality, reliability and speed for each and every CMC package delivered to its partners, announces it enters into a strategic partnership for CMC development and manufacturing with Ansun Biopharma (“Ansun”)

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Reopening schools this fall will require a multi-faceted plan that involves healthy building control strategies, proper ventilation and filtration, disinfection and maintenance, and masks, says a panel of healthy building experts.

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, announced today the closing of its previously announced underwritten public offering of 4,531,434 shares of common stock of the Company,

Increased prevalence of various degenerative bone disease, such as rheumatoid arthritis, curvature of the spine, bone cancer, and cervical spondylitis is estimated to accelerate the growth of the global orthopedic devices market in the forthcoming years.

According to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030. Major depressive disorder, schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders, and anxiety disorder are some of the different types of depression.

Radiosurgery treatment uses focused beams of special ionized radiations directed at the patient. It is primarily used to treat tumors.

NeuPath Health Inc. (TSXV:NPTH) (formerly Klinik Health Ventures Corp.) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, today announced its financial and operating results for the three and six months ended June 30, 2020. For further details on the results, please refer to NeuPath

Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease